

REMARKS

Claims 1-2, 6-11, 13, and 17-25 are pending and under consideration. Claims 1-9, 11-19, 22, and 24 have been canceled. Claims 10, 20, 21, and 23 are amended. Claims 26-29 are new. Support for the amendments and new claims can be found in the specification as published (U.S. Application Publication No. 2007/0167385), for example, in paragraphs [0033], [0054], [0056]-[0058], [0062], [0067], [0114], [0128], and [0173]-[0175], and the claims as originally filed. No new matter is added.

Amendment of the originally filed claims, or cancellation of any claims should in no way be construed as an acquiescence, narrowing, or surrender of any subject matter. The amendments are being made not only to point out with particularity and to claim the present invention, but also to expedite prosecution of the present application. Applicants reserve the right to pursue the subject matter of the canceled claims in this application or a subsequently filed application.

In response to the Restriction Requirement dated July 28, 2008, Applicants hereby elect, with traverse, the invention of **Group I**, namely the subject matter defined by amended claims 10 and 20, and new claims 26-29 for further examination. Applicants believe that the amended claims and new claims properly fall into Group I. Applicants respectfully request reconsideration and withdrawal of this restriction requirement as applied to Group II, insofar as a search for publications relating to the claims of Group I should reveal publications relating to Group II and, thus, would not impose a serious burden on the Examiner. Accordingly, Applicants request rejoinder of Groups I and II.

The Office has also required Applicants to elect a single antisense sequence, *i.e.*, SEQ ID NO: 2, 3, 4, or 15, as indicated in claims 1, 9, 10, 11, and 17 for prosecution on the merits from the invention the Office identifies as Group I.

Applicants hereby elect, with traverse, the antisense sequence identified as **SEQ ID NO: 15** for further examination. Applicants respectfully request reconsideration and withdrawal of this restriction requirement as applied to SEQ ID NOS: 2, 3, 4 and 15.

The Applicants expressly reserve the right to prosecute groups and/or species, and corresponding claims, not elected herein in other patent applications claiming the benefit of the filing date of this application.

Applicant believes that amended claims 10 and 20, and new claims 26-29 read on the aforesaid elections.

CONCLUSION

For completion of the record, the undersigned wishes to draw the Examiner's attention to related applications, U.S. Serial No. 11/501,756, which is subject to a similar Restriction Requirement.

Applicant respectfully requests that the application now proceed promptly to examination. The Examiner is invited to contact the undersigned with any questions about this paper. Early favorable action is respectfully solicited.

Respectfully submitted,

Date: October 28, 2007
Reg. No. 57,961

Tel. No.: (617) 570-8382
Fax No.: (617) 523-1231

LIBC/3416965.1

/Charlene A. Stern-Dombal/
Charlene A. Stern-Dombal
Agent for Applicant
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Goodwin Customer No. 051414